N6F11
Based on 1 publication(s) in Google Scholar
N6F11 is a selective ferroptosis inducer, and can selectively induce ferroptosis by targeting TRIM25-mediated GPX4 degradation in cancer cells while sparing immune cells. N6F11 initiates HMGB1-dependent antitumor immunity mediated by CD8+ T cells.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.11%
- CAS No.: 851398-76-0
- Formule: C13H8Cl2N2OS
- Masse moléculaire:311.19
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Cancer Compound Library
HY-L025
-
Ferroptosis Compound Library
HY-L051
-
Transcription Factor-Targeted Library
HY-L090
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) N6F11
More
Activité biologique
N6F11 (5 μM, 12 h) suppresses GPX4 expression through enhanced protein degradation instead of through reduced gene transcription, induces autophagy-independent ferroptosis in PANC1 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 851398-76-0
-
Appearance Solid
-
Masse moléculaire 311.19
-
Formule C13H8Cl2N2OS
-
Color Off-white to light yellow
-
SMILES
ClC1=CC=C(C2=CC3=C(C(NC(CCl)=N3)=O)S2)C=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Death Discov
Exploiting dysregulated iron homeostasis to eradicate persistent high-grade serous ovarian cancer. [Abstract]2025 Sep 25;11(1):423. PMID: 40998801
Solvant et solubilité
DMSO : 31.25 mg/mL (100.42 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Pureté et documentation
-
Fiche technique (271 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Li J, et al. Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer. Sci Transl Med. 2023;15(720):eadg3049. [Content Brief]
[2]. Liu J, et al. Cell type-specific induction of ferroptosis to boost antitumor immunity. Oncoimmunology. 2023 Nov 20;12(1):2282252. [Content Brief]
[3]. Shi TM, et al. Ferroptosis-Based Therapeutic Strategies toward Precision Medicine for Cancer. J Med Chem. 2024 Feb 22;67(4):2238-2263. [Content Brief]
[4]. Liu J, et al. Adverse effects of ferroptotic therapy: mechanisms and management. Trends Cancer. 2024 May;10(5):417-429. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2135 mL | 16.0674 mL | 32.1347 mL | 80.3368 mL |
| 5 mM | 0.6427 mL | 3.2135 mL | 6.4269 mL | 16.0674 mL | |
| 10 mM | 0.3213 mL | 1.6067 mL | 3.2135 mL | 8.0337 mL | |
| 15 mM | 0.2142 mL | 1.0712 mL | 2.1423 mL | 5.3558 mL | |
| 20 mM | 0.1607 mL | 0.8034 mL | 1.6067 mL | 4.0168 mL | |
| 25 mM | 0.1285 mL | 0.6427 mL | 1.2854 mL | 3.2135 mL | |
| 30 mM | 0.1071 mL | 0.5356 mL | 1.0712 mL | 2.6779 mL | |
| 40 mM | 0.0803 mL | 0.4017 mL | 0.8034 mL | 2.0084 mL | |
| 50 mM | 0.0643 mL | 0.3213 mL | 0.6427 mL | 1.6067 mL | |
| 60 mM | 0.0536 mL | 0.2678 mL | 0.5356 mL | 1.3389 mL | |
| 80 mM | 0.0402 mL | 0.2008 mL | 0.4017 mL | 1.0042 mL | |
| 100 mM | 0.0321 mL | 0.1607 mL | 0.3213 mL | 0.8034 mL |
Powered by Bioz